Daiichi-Sankyo’s new combination form approved by KFDA

Published: 2012-09-18 06:57:00

Updated: 2012-09-18 06:57:00

Daiichi-Sankyo Korea said Sunday it has received approval from the Korea Food and Drug Administration to market Servicar HCT, a new combination treatments containing three drugs.

Sevikar HCT is a single pill, fixed-dose triple combination of three anti-hypertensive agents indicated for the treatment of patients with hypertension. The three anti-hypertensive agents are: olmesartan medoxomil (...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.